Dyne Therapeutics Inc
NASDAQ:DYN
Dyne Therapeutics Inc
NASDAQ:DYN
Price:
25.65 USD
-2.29%
Market Closed
Updated:
May 8, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of DYN.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
DYN
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
DYN Competitors Multiples
Dyne Therapeutics Inc Competitors
Dyne Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Dyne Therapeutics Inc
NASDAQ:DYN
|
2.2B USD | 0 | -8.7 | -6.7 | -6.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 59.6 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
161.1B USD | 5.5 | 42.8 | 18.2 | 30 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
105.7B USD | 10.7 | 29.2 | 23.4 | 24.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
106.9B USD | 8.2 | 27.7 | 22.4 | 24.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.1B AUD | 6.3 | 36 | 21.8 | 27 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 168.5 | 6.8 | 8.9 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.4B USD | 9 | -7.8 | -8.4 | -7.5 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.9B USD | 3.3 | 27.3 | 14 | 17.5 | |
| KR |
|
Celltrion Inc
KRX:068270
|
40.3T KRW | 18.5 | 75.2 | 46 | 63.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
